Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Marcia Macphearson

Partner, Health & Life Sciences, Oliver Wyman

Specialty drugs represent an opportunity to better serve patients, but also pose risks.

Partner, Health & Life Sciences, Oliver Wyman
Principal, Actuarial, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Fourteen percent of physicians offer virtual visits. But a new CMS rule may make telehealth more commonplace.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

Five success factors for accelerating innovation through strategic partnerships.

Partner, Health & Life Sciences, Oliver Wyman

Today's market requires a new approach to medical cost management. Learn about common pitfalls and five program must-haves.

Partner, Health and Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman

Two scenarios for how repeal and replace changes might unfold.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

Now is the time -- why insurers must better understand the unique needs of the ACA population.

Partner, Health & Life Sciences, Oliver Wyman

Powerful new consumer tools are shedding light on previously hidden service costs and quality outcomes in healthcare. Yet, a closer look reveals that transparency solutions may have unintended, less-than-favorable consequences for consumers.

Senior Vice President, Health Care Value, BCBSM
Partner, Health & Life Sciences, Oliver Wyman